Foresight Diagnostics Announces Study Demonstrating Prognostic Utility of PhasED-Seq™ for MRD Assessment after Frontline DLBCL Treatment at the 17th International Conference on Malignant Lymphoma

AURORA, Colo., June 13, 2023 /PRNewswire/ — Foresight Diagnostics, the leader in ultrasensitive minimal residual disease (MRD) detection technology, announced today that Mark Roschewski, MD, of the National Cancer Institute, part of the National Institutes of Health, will present pooled…

Click here to view original post